- Investing Ideas
- U.S. Pharmaceuticals & Biotech Breakout Stocks
U.S. Pharmaceuticals & Biotech Breakout Stocks
Results
16
Stocks where the price continues to rise after more than a year of consistent gains.
16 companies
10x Genomics
Market Cap: US$5.3b
Develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
TXG
US$45.79
7D
21.0%
1Y
274.7%
Forte Biosciences
Market Cap: US$1.1b
Operates as a clinical-stage biopharmaceutical company in the United States.
FBRX
US$43.20
7D
94.2%
1Y
357.1%
Faeth Therapeutics
Market Cap: US$860.0m
A clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients.
FTH
US$33.12
7D
26.8%
1Y
316.6%
Q32 Bio
Market Cap: US$362.5m
A clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.
QTTB
US$18.46
7D
35.5%
1Y
787.5%
Cibus
Market Cap: US$162.6m
An agricultural biotechnology company that develops and licenses gene-edited plant traits.
CBUS
US$2.39
7D
59.3%
1Y
52.2%
Fortress Biotech
Market Cap: US$109.6m
Operates as a biopharmaceutical company in the United States and internationally.
FBIO
US$3.73
7D
24.7%
1Y
92.3%
New Green Hemp
Market Cap: US$37.6m
New Green Hemp Inc. cultivates and sells hemp products.
NGHI
US$1.53
7D
33.0%
1Y
98.0%
NanoViricides
Market Cap: US$37.6m
A clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections.
NNVC
US$1.77
7D
20.4%
1Y
21.2%
EOM Pharmaceuticals Holdings
Market Cap: US$34.1m
A clinical-stage biotechnology company, focuses on the development of drugs to transform therapeutic paradigms and enhance quality of life in patients suffering from debilitating and deadly diseases in the United States.
IMUC
US$0.27
7D
34.9%
1Y
249.2%
Greater Cannabis Company
Market Cap: US$238.6k
Engages in the development and commercialization of cannabinoid therapeutics.
GCAN
US$0.25
7D
28.9%
1Y
66.7%
Innovation Pharmaceuticals
Market Cap: US$158.6k
A clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective.
IPIX
US$0.0005
7D
66.7%
1Y
66.7%
PaxMedica
Market Cap: US$88.4k
A clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms.
PXMD
US$0.0007
7D
40.0%
1Y
600.0%
Navidea Biopharmaceuticals
Market Cap: US$20.0k
A biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics.
NAVB.Q
US$0.0002
7D
100.0%
1Y
0%
Anthera Pharmaceuticals
Market Cap: US$2.6k
A biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs.
ANTH
US$0.0001
7D
9,900.0%
1Y
0%
AmeriCann
Market Cap: US$2.4k
Designs, develops, leases, and operates cannabis cultivation, processing, and manufacturing facilities in the United States.
ACAN
US$0.0001
7D
900.0%
1Y
0%
Khiron Life Sciences
Market Cap: US$2.3k
Operates as a medical cannabis company in Latin America and Europe.
KHRN.F
US$0.00001
7D
900.0%
1Y
0%